Literature DB >> 3785666

The effect of diazepam upon local cerebral glucose use in the conscious rat.

P A Kelly, I Ford, J McCulloch.   

Abstract

The effects of diazepam (0.1-1.0 mg/kg i.v.) upon local cerebral glucose utilization, were analysed in 61 anatomically discrete areas of the conscious rat brain using [14C]-2-deoxyglucose quantitative autoradiography. The administration of diazepam resulted in significant reductions in the rate of glucose use in every region investigated. The regional pattern of alterations in glucose utilization was rather homogeneous, with the majority of brain regions analysed showing reductions of between 20 and 40% in response to 0.3 mg/kg diazepam. Only two regions of the central nervous system differed significantly from the widespread, homogeneous reductions. In the mammillary body, the rate of glucose utilization was more sensitive to depression than elsewhere in the brain (55% reductions following 0.3 mg/kg diazepam), whilst in the lateral amygdala, the rate of glucose use was less sensitive (8% reductions following 0.3 mg/kg diazepam). The effects of diazepam were compared to those elicited by i.v. injection of the gamma-aminobutyric acid (GABA) agonists, muscimol and tetrahydroisoxazolopyridinol (THIP), as reported previously by the authors. Although muscimol and THIP, like diazepam, reduced glucose use in every region of the brain, visual inspection of the autoradiograms suggested that whilst the patterns of regional responsiveness to the two GABA agonists were almost identical, they were different to the pattern of response evoked by diazepam. A rigorous system of analysis was devised making use of the dose-response profiles in each of the 61 brain areas to construct a regional hierarchy of responsiveness to the three drugs and allowing comparison of their effects on the brain as a whole. This critical form of data evaluation revealed that there was a more regionally homogeneous response to diazepam than to either muscimol or THIP, and whilst the regional hierarchy of responses to the GABA agonists was very similar, both differed from diazepam. It would appear that whilst benzodiazepines may interact with the GABA receptor, their effects upon the integrated functional activity of the brain as a whole differs markedly from that evoked by putative GABA receptor agonists.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3785666     DOI: 10.1016/0306-4522(86)90019-9

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  5 in total

1.  Benzodiazepine receptors mediate regional blood flow changes in the living human brain.

Authors:  E Matthew; P Andreason; K Pettigrew; R E Carson; P Herscovitch; R Cohen; C King; C E Johanson; D J Greenblatt; S M Paul
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

2.  Piracetam and TRH analogues antagonise inhibition by barbiturates, diazepam, melatonin and galanin of human erythrocyte D-glucose transport.

Authors:  Richard J Naftalin; Philip Cunningham; Iram Afzal-Ahmed
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

3.  GABA uptake into astrocytes is not associated with significant metabolic cost: implications for brain imaging of inhibitory transmission.

Authors:  Jean-Yves Chatton; Luc Pellerin; Pierre J Magistretti
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-06       Impact factor: 11.205

4.  Prototypic GABA(A) receptor agonist muscimol acts preferentially through forebrain high-affinity binding sites.

Authors:  Dev Chandra; Lauri M Halonen; Anni-Maija Linden; Chiara Procaccini; Kati Hellsten; Gregg E Homanics; Esa R Korpi
Journal:  Neuropsychopharmacology       Date:  2009-12-23       Impact factor: 7.853

5.  Multimodal imaging of human brain activity: rational, biophysical aspects and modes of integration.

Authors:  Katarzyna Blinowska; Gernot Müller-Putz; Vera Kaiser; Laura Astolfi; Katrien Vanderperren; Sabine Van Huffel; Louis Lemieux
Journal:  Comput Intell Neurosci       Date:  2009-06-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.